Leaflet: information for the patient
Herbion lozenges
Dried extract of Hedera helix (ivy) leaf
Read this leaflet carefully before you start taking this medicine, as it contains important information for you.
Follow exactly the administration instructions contained in this leaflet or those given by your doctor or pharmacist.
1.What is Herbion and what it is used for
2.What you need to know before starting to take Herbion
3.How to take Herbion
4.Possible side effects
5.Storage of Herbion
6.Contents of the pack and additional information
Herbion contains dried extract of ivy leaf.
Herbion is a plant-based medication used as an expectorant for productive cough in adults, adolescents, and children aged 6 years and above.
Do not takeHerbion
Do not administer the medication to children under 2 years of age, as there is a risk of worsening respiratory symptoms.
Warnings and precautions
Consult your doctor or pharmacist before starting to take Herbion:
Children
Herbion chewable tablets are not recommended for use in children aged 2 to 5 years, as it is not possible to adjust the dose in the chewable tablet formulation. In this age range, a syrup formulation is recommended.
In children aged 2 to 4 years with persistent or recurrent cough, a medical diagnosis is required before starting treatment.
Other medications and Herbion
Inform your doctor or pharmacist if you are taking, have taken recently or may need to take any other medication.
No interaction has been reported between the dry extract of ivy leaf and other medications.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or if you think you may be pregnant or plan to become pregnant, consult your doctor or pharmacist before using this medication.
Herbion is not recommended during pregnancy or breastfeeding due to the lack of data on the use of ivy extract in pregnant women or breastfeeding mothers.
Driving and operating machinery
No studies have been conducted on the ability to drive and operate machinery.
Herbion contains isomaltosa (type M) (E953) and butylhydroxyanisole (E320)
This medication contains isomaltosa. If your doctor has indicated that you have an intolerance to certain sugars, consult with them before taking this medication.
This medication may cause local skin reactions (such as contact dermatitis) or irritation of the eyes and mucous membranes because it contains butylhydroxyanisole.
Follow exactly the administration instructions indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist.
The usual dose foradults, elderly patients, and adolescents over 12 years of ageis 1 lozenge, 3 times a day.
Use in children
The usual dose forchildren aged 6 to 11 yearsis 1 lozenge, 2 times a day.
The use of Herbion lozenges is not recommended in children under 6 years of age.
Disintegrate the lozenge in the mouth. Do not take the lozenges immediately before or during meals.
It is recommended to drink plenty of water or other hot, caffeine-free beverages while taking Herbion.
If symptoms persist for more than 1 week during use of this medication, consult your doctor or pharmacist.
If you take more Herbion than you should
Do not take more doses than recommended. Taking higher doses than recommended (more than double the daily dose) may cause nausea, vomiting, diarrhea, and agitation. Treatment is symptomatic.
If you have forgotten to take Herbion
Do not take a double dose to compensate for the missed doses.
If you have any other questions about the use of this medication, consult your doctor or pharmacist.
Like all medications, this medication may produce adverse effects, although not all people will experience them.
With an unknown frequency (the frequency cannot be estimated from the available data):
If you experience an allergic reaction, stop taking the medication and consult with your doctor. In the case of a severe allergic reaction, go to an emergency doctor.
Reporting Adverse Effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that does not appear in this prospectus. You can also report them directly through the Spanish System for Pharmacovigilance of Medicinal Products for Human Use:https://www.notificaram.es.By reporting adverse effects, you can contribute to providing more information about the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging after CAD. The expiration date is the last day of the month indicated.
Do not store above 25°C.
Store in the original packaging to protect it from moisture.
Medications should not be disposed of through drains or trash. Dispose of packaging and medications you no longer need at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of packaging and medications you no longer need. By doing so, you will help protect the environment.
Composition of Herbion
Extractant solvent with 30% (m/m) ethanol.
Appearance of the product and contents of the package
The lozenges are light brown to brown, round, with beveled edges and a rough surface. There may be yellow to brown particles, lighter areas, air bubbles, and slightly toothed edges. Diameter of the lozenges: 18.0 mm – 19.0 mm, thickness: 7.0 mm – 8.0 mm.
The medicine is presented in a blister (PVC/PE/PVDC-Al), in formats of 8, 16 and 24 lozenges.
Only some package sizes may be marketed.
Marketing authorization holder and responsible manufacturer
KRKA d.d. Novo mesto Smarjeska cesta 6 8501 Novo mesto, Slovenia
For more information about this medicine, please contact the local representative of the marketing authorization holder:
Krka Farmacéutica, S.L., C/ Anabel Segura 10, 28108 Alcobendas, Madrid, Spain
This medicine is authorized in the member states of the European Economic Area with the following names:
Member state name | Medicine name |
Slovenia | List navadnega bršljana Krka pastile |
Spain | Herbion lozenges |
Croatia | Herbion pastile od bršljana |
Portugal | Herbihelix Expetorante |
Last review date of this leaflet:February 2024
Detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/.
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.